STOCK TITAN
  1. Home
  2. News
  3. THMO

ThermoGenesis Holdings, Inc. - $THMO STOCK NEWS

Welcome to our dedicated page for ThermoGenesis Holdings news (Ticker: $THMO), a resource for investors and traders seeking the latest updates and insights on ThermoGenesis Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ThermoGenesis Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ThermoGenesis Holdings's position in the market.

News
ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) reported Q3 2023 financial results, highlighting a 3.7% increase in net revenues and a $3,615,000 net loss. The company also unveiled a new 35,500+ square foot CDMO facility in Sacramento, aiming to accelerate product development in the cell and gene therapy field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.18%
Tags
earnings
-
News
ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic Update
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) announces Q3 financial results release and corporate update conference call on November 13, 2023. The company is a market leader in automated cell processing tools and services in the cell and gene therapy field. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada) or access a live webcast at https://thermogenesis.com/investors/news-and-events/events-webcasts/.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
earnings
-
News
ThermoGenesis to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater Sacramento
Rhea-AI Summary
ThermoGenesis Holdings, Inc. announced the grand opening of its new facility, housing ISO 7 cGMP cleanroom suites and research labs. The facility will provide the cleanroom environment and services needed for R&D and manufacturing of cell and gene therapies. ThermoGenesis plans to transform into a cell and gene therapy services company and a contract development and manufacturing organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
News
ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will present a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 13. CEO Chris Xu will also host one-on-one meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences
-
News
ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) reported financial and operating results for the second quarter ended June 30, 2023, with net revenues of $2.3 million, a decrease from the previous year. The company also highlighted the construction of innovative ReadyStart suites in Sacramento and the addition of new independent directors to the Board. ThermoGenesis will host a conference call to discuss these results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
earnings
-
News
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic Update
Rhea-AI Summary
ThermoGenesis Holdings, Inc. will release its financial results for Q2 2023 and provide a corporate strategic update on August 10, 2023. A conference call and webcast will follow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
earnings
News
ThermoGenesis Expands Board of Directors with the Appointments of Dr. Biao Xi and Dr. James Xu
Rhea-AI Summary
ThermoGenesis Holdings, Inc. appoints Biao Xi and James Xu to its Board of Directors. Xi is a highly regarded life science executive with extensive experience in biopharmaceutical research and drug development, while Xu brings strong legal and business acumen. Their expertise will strengthen ThermoGenesis' transition into a high-performance contract development and manufacturing organization in the cell and gene therapy field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
management
-
News
ThermoGenesis Holdings Announces First Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
earnings
-
News
ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide a Corporate Strategic Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
ThermoGenesis Holdings Announces Year End 2022 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
earnings
Stock THMO logo
ThermoGenesis Holdings, Inc.

Nasdaq:THMO

THMO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

THMO Stock Data

5.42M
1.38M
4.11%
2.27%
1.76%
Other Industrial Machinery Manufacturing
Manufacturing
Link
United States of America
RANCHO CORDOVA

About THMO

thermogenesis holdings, inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (car)-t and other cell-based therapies. it markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed car-txpress platform, which streamlines the manufacturing process for the emerging car-t immunotherapy market. the company operates through two segments, device and clinical development. it manufactures and markets products for clinical bio-banking applications, including axp automated cell separation system, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and bioarchive automated cryopreservation system, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical appli